Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa
Key facts
- Who runs it
- Region Skane
- Where
- Sweden1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 40 people, planned
- Started
- 20 Jul 2026
- Expected to end
- 1 Oct 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Psilocybin
- Record updated
- 14 August 2026
Who can take part
- Age
- 16 years to 35 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Diagnosis of AN per DSM-5, including anorexia nervosa in partial remission
- Have experienced at least one period of weight restoration to a minimum BMI of 17 followed by subsequent weight loss
- Age 16-35
- BMI >16
- Stable contact with a psychiatric unit
- Ability to provide informed consent
Who cannot take part
- Ongoing treatment with medications that have clinically relevant 5-HT2A-receptor antagonistic properties and are therefore expected to directly block or substantially interfere with the pharmacodynamic effects of psilocybin. Such medications require an appropriate washout period prior to psilocybin administration, based on pharmacokinetic properties and clinical judgement. Medications without direct 5-HT2A-antagonistic effects are not excluded on this basis
- BMI > 21.0 for ≥ 6 consecutive months within the 12 months prior to screening, as documented in medical records
- Psychosis, bipolar disorder, substance use disorder, family history of psychosis or bipolar disorder, refusal of birth control, lifetime psychedelic use
- Cardiovascular conditions
- History of stroke, myocardial infarction, or other significant cardiovascular events
- Seizure disorders or history of epilepsy
- Diabetes mellitus, positive drug tests, suicidal intent, allergy or intolerance to drug content, blood or needle phobia
- Any other clinically significant medical condition that, in the investigator's opinion, may pose a risk to the participant or interfere with study results
- Care under the Swedish Compulsory Psychiatric Care Act (LPT)
- Clinically significant arrhythmias, tachycardia and QT prolongation
- Resting systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg at screening or baseline
- Only for the MRI-part of the study: Metal pieces in the body (contraindicated by fMRI, assessed in each case by MR-technician). Non-compliance to fMRI will not lead to study exclusion
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 35 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if psilocybin, given with psychological support, is safe and helps treat anorexia nervosa in young adults. Anorexia nervosa is a serious eating disorder that currently has no approved medicine. Psilocybin is a psychedelic substance that may help the brain form new connections, which could make it easier for people with anorexia nervosa to develop healthier ways of thinking.
Read full original descriptionShow less
The main questions this study aims to answer are:
* Is psilocybin with psychological support safe and well-tolerated? * Does psilocybin with psychological support help lower symptoms of anorexia nervosa? * How might psilocybin work in the brain to support recovery from anorexia?
This study will compare psilocybin with psychological support to Treatment as Usual (TAU). Participants in the study will be randomly placed into one of the two groups. There will be 40 patients with anorexia nervosa included, 20 per group. TAU includes the standard care people receive for anorexia nervosa in a specialized eating disorder clinic in Region Skåne, Sweden.
Participants will:
* Be between 16 and 35 years old and have anorexia nervosa * Take psilocybin (25 mg) by mouth two times, four weeks apart * Receive psychological support before, during, and after each dosing session (including preparation and integration sessions) * Complete questionnaires, have brain scans (magnetic resonance imaging) and blood tests to learn more about how psilocybin may work * Share their personal experiences as part of a qualitative interview
This study hopes to learn if psilocybin, when given with the right support, can be a helpful and safe option for people living with anorexia nervosa.
The 2 groups in the trial
- Psilocybin with Psychological SupportExisting treatment, for comparison
This arm will receive two separate doses of psilocybin 25 mg administered four weeks apart, with psychological support, along side treatment as usual. The psychological support includes preparation sessions before, support during, and integration sessions after psilocybin intake.
Treatment: Psilocybin
- Treatment as UsualNo study treatment, for comparison
This arm will receive treatment as usual which includes specialised care offered in an eating disorder unit in Region Skåne, Sweden. If the active treatment arm is determined to be safe, tolerable, and preliminarily effective during the follow-up assessment at 6 months, participants in the control group will have the option to switch to the active treatment while maintaining their usual specialised care.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults
- Fit questions
- Built from NCT07169747, who can take part
- Publications
- Record updated
- 14 August 2026